ARRIVENT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.41 USD | +2.68% |
|
+0.77% | 0.00% |
| Jun. 24 | ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Global BMI Index | CI |
| Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 616.6 | - | - |
| Enterprise Value (EV) 1 | 415.9 | 114.8 | 224.4 |
| P/E ratio | -6.34 x | -5.94 x | -5.68 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | 47.8 x |
| EV / Revenue | - | - | 17.4 x |
| EV / EBITDA | -4.66 x | -1.02 x | -1.67 x |
| EV / FCF | -6.97 x | -1.68 x | -2.85 x |
| FCF Yield | -14.4% | -59.7% | -35% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 33,494 | - | - |
| Reference price 2 | 18.41 | 18.41 | 18.41 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 12.9 |
| EBITDA 1 | - | -74.59 | -89.23 | -113 | -134.3 |
| EBIT 1 | - | -74.59 | -100.7 | -104.2 | -110.7 |
| Operating Margin | - | - | - | - | -858.42% |
| Earnings before Tax (EBT) 1 | - | -69.33 | -75.81 | -92.18 | -101.4 |
| Net income 1 | -36.91 | -69.33 | -75.81 | -92.18 | -101.4 |
| Net margin | - | - | - | - | -786.29% |
| EPS 2 | -1.900 | -32.38 | -2.904 | -3.100 | -3.240 |
| Free Cash Flow 1 | - | -61.1 | -59.7 | -68.5 | -78.6 |
| FCF margin | - | - | - | - | -609.3% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/25/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | -20.67 | -21.58 | -22.52 | -24.45 | - | - |
| EBIT 1 | -20.67 | -22.61 | -33.44 | -24.39 | -24.47 | -25.13 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -17.42 | -19 | -20.05 | -19.85 | -21.23 | -22.14 |
| Net income 1 | -17.42 | -19 | -20.05 | -19.85 | -21.23 | -22.14 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.7000 | -0.6278 | -0.6585 | -0.6390 | -0.6300 | -0.6500 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 150 | 201 | 502 | 392 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -61.1 | -59.7 | -68.5 | -78.6 |
| ROE (net income / shareholders' equity) | - | - | -15.8% | -3.94% | -3.99% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | - | - | 0.5 |
| Capex / Sales | - | - | - | - | 3.88% |
| Announcement Date | 8/25/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.41
USD
Average target price
30.2
USD
Spread / Average Target
+64.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 601M | |
| +23.50% | 45.01B | |
| +47.19% | 40.96B | |
| -5.16% | 38.62B | |
| +36.37% | 32.6B | |
| -7.79% | 27.49B | |
| +18.06% | 27.17B | |
| +47.29% | 14.61B | |
| +41.91% | 12.95B | |
| -1.02% | 11.36B |
- Stock Market
- Equities
- AVBP Stock
- Financials ArriVent BioPharma, Inc.
